SCHEDULE: Cyclerion Therapeutics: Hecht Adjusts Stake

Peter M. Hecht amends Schedule 13D, reporting a beneficial ownership of 910,240 shares of Cyclerion Therapeutics' common stock, representing 19.4% of the class.

Summary

• Peter M. Hecht has filed an amendment (Amendment No. 8) to his Schedule 13D beneficial ownership statement for Cyclerion Therapeutics, Inc.
• This amendment updates the statement originally filed on May 14, 2021, and subsequent amendments.
• The Reporting Person now beneficially owns 910,240 shares of Common Stock.
• This ownership represents 19.4% of the total outstanding shares of Common Stock.
• The update reflects the forfeiture of options to purchase 110,984 shares of Common Stock.
• It also includes the conversion of 351,037 shares of non-voting Series A Convertible Preferred Stock into 351,037 shares of Common Stock on July 16, 2026.
• The total number of outstanding shares of Common Stock is stated as 4,681,351 as of June 30, 2026, plus the 351,037 shares issued upon conversion.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, primarily an administrative update reflecting changes in beneficial ownership due to stock conversions and option forfeitures, without new strategic information.

Positives

• Increased beneficial ownership percentage due to conversion of preferred stock.
• Clear disclosure of share ownership and class representation.

Negatives

• Forfeiture of options to purchase 110,984 shares of Common Stock.

Future Outlook

No specific future outlook or guidance is provided in this amendment, which focuses on reporting current beneficial ownership and recent transactions.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are crucial for tracking significant ownership changes by institutional investors and insiders, providing transparency into potential shifts in control or strategic influence within a company.

Stakeholder Impact

• Shareholders: The conversion of preferred stock and forfeiture of options by a significant beneficial owner may influence market perception of the company's capital structure and insider holdings.

Next Steps

• The Reporting Person will continue to hold and potentially manage their beneficial ownership in Cyclerion Therapeutics, Inc.

Key Dates

Keywords

Cyclerion Therapeutics, Schedule 13D, Beneficial Ownership, Common Stock, Preferred Stock Conversion, Securities Exchange Act, Peter M. Hecht, Insider Trading